| Symbol | ERAS |
|---|---|
| Name | ERASCA, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 10835 ROAD TO THE CURE,SUITE 140, SAN DIEGO, California, 92121, United States |
| Telephone | +1 858 465-6511 |
| Fax | — |
| — | |
| Website | https://www.erasca.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001761918 |
| Description | Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The companys pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers. Additional info from NASDAQ: |
Fuchs Charles S. 🟢 acquired 1.3M shares (1 derivative) of Erasca, Inc. (ERAS) at $18.12 ($23.6M) Transaction Date: Aug 10, 2026 | Filing ID: 346924
Read moreNew Form 3 - Erasca, Inc. <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0001193125-26-346920 <b>Size:</b> 3 KB
Read moreErasca Reports Second Quarter 2026 Business Updates and Financial Results
Read moreNew Form S-8 - Erasca, Inc. <b>Filed:</b> 2026-08-11 <b>AccNo:</b> 0001193125-26-344845 <b>Size:</b> 382 KB
Read moreERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law
Read moreCLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
Read moreErasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | Phase1 | Metastatic Solid Tumors | Recruiting | 2025-08-06 | 2028-12-01 | ClinicalTrials.gov |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase1 | Metastatic Solid Tumors | Recruiting | 2025-06-05 | 2028-12-01 | ClinicalTrials.gov |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patien… | Phase3 | Advanced or Metastatic NRAS-mutant Melanoma | Active_Not_Recruiting | 2024-04-29 | 2028-12-01 | ClinicalTrials.gov |
| NCT05907304 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patien… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2023-08-17 | 2026-12-01 | ClinicalTrials.gov |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With He… | Phase1 | Acute Myeloid Leukemia | Withdrawn | 2022-03-15 | 2025-06-01 | ClinicalTrials.gov |
| NCT05222802 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBB… | Phase1 | Glioblastoma Multiforme | Active_Not_Recruiting | 2022-02-25 | 2025-09-30 | ClinicalTrials.gov |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | Phase1 | Metastatic Colorectal Cancer | Completed | 2021-09-20 | 2026-01-26 | ClinicalTrials.gov |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Ad… | Phase1 | Advanced Non-squamous Non-small-cell Lung Cancer | Completed | 2021-09-02 | 2023-04-27 | ClinicalTrials.gov |
| NCT04866134 | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients … | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2021-05-07 | 2027-01-01 | ClinicalTrials.gov |
| NCT04670679 | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Meta… | Phase1 | Advanced or Metastatic Solid Tumors | Active_Not_Recruiting | 2020-12-15 | 2026-06-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-007 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| Gilteritinib | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-601 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-007 | Other | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| Sotorasib | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| Osimertinib | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-601 | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-007 | Other | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-007 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04866134 |
| ERAS-801 | Other | Phase PHASE1 | Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | NCT05222802 |
| ERAS-0015 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-4001 in combination | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-4001 | Other | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| Trametinib | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Temozolomide | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Dacarbazine | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Naporafenib | Other | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Trametinib | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05907304 |
| Naporafenib | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT05907304 |
| Palbociclib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Cetuximab | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Encorafenib | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| ERAS-007 | Other | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| Cetuximab | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| ERAS-601 | Other | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| ERAS-4001 in combination | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-4001 | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT07021898 |
| ERAS-0015 in combination | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| ERAS-0015 | DRUG | Phase PHASE1 | Metastatic Solid Tumors | RECRUITING | NCT06983743 |
| Temozolomide | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Dacarbazine | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Trametinib | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Naporafenib | DRUG | Phase PHASE3 | Advanced or Metastatic NRAS-mutant Melanoma | ACTIVE_NOT_RECRUITING | NCT06346067 |
| Gilteritinib | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| ERAS-801 | DRUG | Phase PHASE1 | Glioblastoma Multiforme | ACTIVE_NOT_RECRUITING | NCT05222802 |
| Palbociclib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Encorafenib | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| Sotorasib | DRUG | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| Osimertinib | DRUG | Phase PHASE1 | Advanced Non-squamous Non-small-cell Lung Cancer | COMPLETED | NCT04959981 |
| ERAS-007 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | NCT04670679 |
| Cetuximab | DRUG | Phase PHASE1 | Metastatic Colorectal Cancer | COMPLETED | NCT05039177 |
| ERAS-601 | DRUG | Phase PHASE1 | Acute Myeloid Leukemia | WITHDRAWN | NCT05279859 |